CEL-SCI Collaborators Present Data Suggesting That LEAPS Technology Has Ability to Modify Immune Response

CEL-SCI Collaborators Present Data Suggesting That LEAPS Technology Has
Ability to Modify Immune Response
STUDIES SUPPORTIVE OF ROLE THAT TECHNOLOGY CAN PLAY IN TREATMENT OF H1N1
HOSPITALIZED PATIENTS

VIENNA, Va., Nov. 9 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE Amex:
CVM) announced today that Dr. Kenneth S. Rosenthal, Professor of Immunology
and Microbiology of Northeastern Ohio Universities College of Medicine and
Pharmacy, reported on work conducted in collaboration with scientists at the
Cleveland Clinic and CEL-SCI on CEL-SCI's LEAPS vaccine technology. The data
was presented at the 7th GTCbio Vaccine: "All Things Considered" Conference in
Crystal City, Virginia.

Working with LEAPS vaccines for herpes simplex virus, HIV, rheumatoid
arthritis and most recently, H1N1 influenza, the scientists' studies show that
LEAPS peptide immunogens can convert precursor cells from mouse or humans to
become dendritic cells (DC), the cell that directs the subsequent immune
response. These DCs produce interleukin 12 (IL12p70), but without production
of the pro-inflammatory cytokines that promote symptoms of a cytokine storm,
such as tumor necrosis factor alpha or interleukin 1. Immunization with a
LEAPS-immunogen for herpes simplex virus activates a protective T cell immune
response against the virus in mice while a LEAPS-immunogen for treatment of
rheumatoid arthritis (CEL-2000) reduces the production of the pro-inflammatory
cytokines to block the progression of disease in mouse models of rheumatoid
arthritis.

Dr. Rosenthal commented, "LEAPS immunogens are unique in their ability to
simultaneously produce and activate a specific type of dendritic cell that can
turn on or modulate antigen specific T cell responses without generating the
pro-inflammatory cytokines associated with cytokine storm. The ability to
activate the desired immune response should make LEAPS immunogens inherently
safe vaccines. Finding of similar results for mouse and human cells in our
laboratory studies adds confidence that the effects in the body will be the
same in mice and man. "

Geert Kersten, CEO of CEL-SCI Corporation said: "We feel that this new data is
encouraging and supportive of our H1N1 treatment for hospitalized patients
where the goal is to produce a specific anti H1N1 immune response that will
steer the immune system towards protection and away from a cytokine storm
which may be responsible for many patients' deaths."

CEL-SCI's L.E.A.P.S.(TM) (Ligand Epitope Antigen Presentation System)
technology allows the Company to direct an immune response against specific
disease epitopes. In the case of CEL-SCI's investigational LEAPS-H1N1
treatment, this involves non-changing regions of H1N1 Pandemic Flu, Avian Flu
(H5N1), and the Spanish Flu. This is intended to enable stimulation of the
specifically-needed immune responses, while avoiding the administration of
regions of H1N1, and other viruses, which may exacerbate the problem of
cytokine storm, which CEL-SCI scientists believe may be involved in the death
of some H1N1 patients.

The concept behind the L.E.A.P.S. technology is to directly mimic cell/cell
interactions on the T-cell surface with synthetic peptides. The L.E.A.P.S.
constructs containing the antigenic disease epitope linked to a Immune /
T-cell binding ligand (I/TCBL) can be manufactured by peptide synthesis or by
covalently linking the two peptides. Depending upon the type of L.E.A.P.S.
construct and I/TCBL used, CEL-SCI is able to direct the outcome of the immune
response towards the development of T-cell function with primarily effector
T-cell functions (T Lymphocyte; helper/effector T lymphocyte, type 1 or 2 [Th1
or Th2], cytotoxic [Tc] or suppressor [Ts]). Therefore, it would appear that
the L.E.A.P.S. construct represents a chimeric peptide with bi-functional
behavior.

CEL-SCI Corporation is developing products that empower immune defenses. Its
lead product is Multikine® which is being readied for a global Phase III trial
in advanced primary head and neck cancer. CEL-SCI is also developing a
treatment for hospitalized H1N1 patients using it's L.E.A.P.S. technology
platform, and expects to soon finish the validation of it's state-of-the-art
manufacturing facility in Maryland.

For more information, please visit www.cel-sci.com

When used in this report, the words "intends," "believes," "anticipated" and
"expects" and similar expressions are intended to identify forward-looking
statements. Such statements are subject to risks and uncertainties which could
cause actual results to differ materially from those projected. Factors that
could cause or contribute to such differences include, lack of regulatory
clearance to proceed with clinical trials, an inability to duplicate the
clinical results demonstrated in clinical studies that have been completed or
that are initiated in the future, timely development of any potential products
that can be shown to be safe and effective, unwillingness of regulatory
authorities to engage in further regulatory dialogue, receiving necessary
regulatory approvals, difficulties in manufacturing any of the Company's
potential products, inability to raise the necessary capital, and the risk
factors set forth from time to time in CEL-SCI Corporation's SEC filings,
including but not limited to its report on Form 10- K/A for the year ended
September 30, 2008. The Company undertakes no obligation to publicly release
the result of any revision to these forward-looking statements which may be
made to reflect the events or circumstances after the date hereof or to
reflect the occurrence of unanticipated events.

SOURCE CEL-SCI Corporation

Gavin de Windt, CEL-SCI Corporation, +1-703-506-9460